Skip to main content

A Study of Eloralintide (LY3841136) and Eloralintide With Tirzepatide in Participants With Overweight or Obesity

Completed · Phase 1 · NCT06916065

Conditions: Overweight, Obesity

At a glance

Research payments reported, 2025
$11.8M
U.S. investigators named
3
Sites paid
4
Planned or actual enrollment
188

About the trial

Sponsor
Eli Lilly and Company
Tested
Eloralintide and Tirzepatide (drug), Eloralintide (drug)
Dates
Started 2025-04-09; completion 2026-01-19
Results posted
Not yet

The purpose of this study is to evaluate how well eloralintide and eloralintide with tirzepatide is tolerated and what side effects may occur in participants with overweight or obesity. The study drug will be administered subcutaneously (SC) (under the skin). Blood tests will be performed to check how much eloralintide and eloralintide with tirzepatide get into the bloodstream and how long it takes the body to eliminate it. There will be 6 cohorts. The study will last up to approximately 26 weeks, excluding screening for Cohorts A and B, 11 weeks for Cohorts C and D, and 12 weeks for Cohorts E and F.

From ClinicalTrials.gov, last updated 2026-01-30. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Eli Lilly and Company reported $11.8M in research payments for this study in 2025 (10 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

  • Covance Clinical Research Unit Inc $4.2M
  • Covance Clinical Research LP Dallas $4.1M
  • Anaheim Clinical Trials LLC $3.5M
  • Collaborative Neuroscience Research LLC $38,503

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.